|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0032200,
umls-concept:C0078058,
umls-concept:C0205250,
umls-concept:C0332464,
umls-concept:C0441655,
umls-concept:C0442027,
umls-concept:C0520484,
umls-concept:C0597357,
umls-concept:C1171892,
umls-concept:C1690540,
umls-concept:C1999216,
umls-concept:C2347295
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-1
|
|
pubmed:abstractText |
Angiogenesis plays a critical role in breast cancer development and progression. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that regulates endothelial cell proliferation and survival. We investigated the effects of motesanib, a novel, oral inhibitor of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit receptor, on the growth of xenografts representing various human breast cancer subtypes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BelmontesBrianB,
pubmed-author:BushTammyT,
pubmed-author:CaenepeelSeanS,
pubmed-author:CoxonAngelaA,
pubmed-author:HughesPaulP,
pubmed-author:KaufmanStephenS,
pubmed-author:KawutS MSM,
pubmed-author:KendallRichardR,
pubmed-author:PatelVinodV,
pubmed-author:PolverinoAnthonyA,
pubmed-author:RadinskyRobertR,
pubmed-author:RottmanJames BJB,
pubmed-author:SaffranDouglasD,
pubmed-author:TaskerAndrewA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
110-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19118038-Angiogenesis Inhibitors,
pubmed-meshheading:19118038-Animals,
pubmed-meshheading:19118038-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19118038-Body Weight,
pubmed-meshheading:19118038-Cell Line, Tumor,
pubmed-meshheading:19118038-Cell Proliferation,
pubmed-meshheading:19118038-Dose-Response Relationship, Drug,
pubmed-meshheading:19118038-Female,
pubmed-meshheading:19118038-Humans,
pubmed-meshheading:19118038-Indoles,
pubmed-meshheading:19118038-Mammary Neoplasms, Experimental,
pubmed-meshheading:19118038-Mice,
pubmed-meshheading:19118038-Mice, Nude,
pubmed-meshheading:19118038-Niacinamide,
pubmed-meshheading:19118038-Platelet-Derived Growth Factor,
pubmed-meshheading:19118038-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:19118038-Random Allocation,
pubmed-meshheading:19118038-Vascular Endothelial Growth Factor A,
pubmed-meshheading:19118038-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
|
|
pubmed:affiliation |
Department of Oncology Research, Amgen, Inc., Thousand Oaks, California, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
